Clinical Trial Detail

NCT ID NCT01217437
Title Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

medulloblastoma

pineoblastoma

Therapies

Irinotecan + Temozolomide

Bevacizumab + Irinotecan + Temozolomide

Age Groups: adult child

No variant requirements are available.